BioScrip, Inc. (NASDAQ:BIOS) registered a 10.95% increase, still its new closing price is 55.10% up from the company’s 1 year high of 3.43.It posted 10.95% gains in previous 5 sessions and is now the subject of 1 analysts who together assign a hold rating on stock. 0 of Wall Street analysts have an underperform rating; the 0 sells versus 2 buy or better ratings. The 6 stock analysts following this company have an average price target at $2.50, with individual PT in the $1.50-$4.50 range. The shares moved at $1.52, implying that brokerage firms see shares losing about -7.88% in twelve months time.
BioScrip, Inc. (BIOS) SEC Form 4 News
The stock is getting much attention these days as insiders are adding shares while they posted a 46.15% rise year to date. A CFO at BioScrip, Inc. (BIOS) acquired shares in a transaction closed on Friday November 11, 2016. Kreger Jeffrey M bought 10,000 shares in the company at $1.32 each and collected $13,000 in proceeds. Kreger Jeffrey M now owns 22,628 shares in the company after this transaction. A CEO in the company, GREENLEAF DANIEL E, disclosed a transaction on Thursday November 10, 2016 that ended up paying $20,001 from the purchase of 16,000 shares at $1.3 per share.
BioScrip, Inc. (NASDAQ:BIOS) Upcoming Results on Tap
BioScrip, Inc. will next provide financial results for the March 2017 quarter. Stock analysts expect it to report per-share earnings of $-0.07 in that period. Sales during the quarter are predicted to arrive at $234.07 million.
Earnings surprise history: Last quarter, the company posted approximately $224.54 million in revenue and EPS of $-0.11. The mean forecast was for $223.26 million and $-0.05 a share, respectively. One quarter earlier, revenue for the stock was at $232.46 million, with earnings at $-0.08/share.
BioScrip, Inc. (BIOS) Brokerage Update
BioScrip, Inc. (BIOS) is in Sun Trust Rbsn Humphrey’s research list so their analyst rating change is noteworthy. These shares were downgraded to Neutral from Buy by Sun Trust Rbsn Humphrey, according to news reported on Tuesday August 11, 2015.Another important research note was issued by Feltl & Co. on Friday November 08, 2013.The firm downgraded BIOS to Buy from Strong Buy. Over the last six months and over the last three months, the shares of BioScrip, Inc. (BIOS), have changed -39.44% and -43.49%, respectively.